ImmuCell reports 2025 net operating income $1.6M; net loss narrows to $1.0M

IMMUCELL CORP /DE/

Product sales $27.6M, up 4.3% YoY; gross margin improved to 41.4% from 30%.
Net loss $1.0M ($0.12/share) vs $2.2M ($0.26/share) in 2024.
Net operating income $1.6M vs operating loss $1.6M in 2024.
Non-recurring items: $2.7M Re-Tain write-down, $651K colostrum write-downs, $297K CEO transition costs, $427K insurance proceeds.
Cash $3.8M, no debt draw; net working capital $13M.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

IMMUCELL CORP /DE/ reported financial results for year ended December 31, 2025.

Period: year ended December 31, 2025
Result: reported results

Exact text from the filing

On March 4, 2026 ImmuCell Corporation (the "Company") issued a press release announcing its unaudited financial results for the quarter and year ended December 31, 2025.

View on SEC.gov

Browse all earnings releases →

IMMUCELL CORP /DE/ filing history →

Source: SEC EDGAR

accession 0001437749-26-006912

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.